|Global Biosimilars Market (2018-2022) to Record a CAGR of Approx 35% - ResearchAndMarkets.com|
|Thursday, 10 January 2019 03:06|
Jan. 10, 2019 11:29 UTC
Global Biosimilars Market (2018-2022) to Record a CAGR of Approx 35% - ResearchAndMarkets.com
The biosimilars market will register a CAGR of almost 35% by 2022.
Patients and physician's willingness to switch to biosimilars is expected to drive growth in the market
Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients are very much willing to shift to biosimilars.
Price advantage of biosimilars over biologics
High cost of biologics reduces patient access to these products and increases the total healthcare costs. The reason for less cost of biosimilar can be sue to the smaller number of clinical trials for a biosimilar when compared with original biologic.
Market access barriers for biosimilars
To compete with biologics and to get entry into the market, the biosimilars are facing challenge. The first and foremost challenge is sophisticated manufacturing process associated with biosimilars.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY APPLICATION
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
PART 15: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/research/mnmcjt/global?w=4
Source: Research and Markets